Cochrane · systematic review · CD012615
Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
Jung, JH, Kim, J, MacDonald, R, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
UrologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
20
current version
GRADE rated
20
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 10%Low 12 · 60%Moderate 6 · 30%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Silodosin compared to placebo for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia (short term)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Urologic symptom scores Silodosin vs placebo | no estimate extracted | 3 studies · 1743 participants | Low Downgraded: risk of bias, imprecision |
QoL Silodosin vs placebo | no estimate extracted | 2 studies · 820 participants | Moderate Downgraded: risk of bias, inconsistency |
Treatment withdrawal due to any reason Silodosin vs placebo | RR 1.08 [0.7, 1.66] | 3 studies · 1703 participants | Low Downgraded: risk of bias, imprecision |
Cardiovascular adverse events Silodosin vs placebo | RR 1.28 [0.67, 2.45] | 4 studies · 1967 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Sexual adverse events Silodosin vs placebo | RR 26.07 [12.36, 54.97] | 4 studies · 1967 participants | Moderate Downgraded: risk of bias |
Silodosin compared to tamsulosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia (short term)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Urologic symptom scores Silodosin vs tamsulosin | no estimate extracted | 10 studies · 1708 participants | Low Downgraded: risk of bias, inconsistency |
QoL Silodosin vs tamsulosin | no estimate extracted | 10 studies · 1707 participants | Low Downgraded: risk of bias, inconsistency |
Treatment withdrawal due to any reason Silodosin vs tamsulosin | RR 1.02 [0.62, 1.69] | 10 studies · 1573 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Cardiovascular adverse events Silodosin vs tamsulosin | RR 0.77 [0.53, 1.12] | 11 studies · 1955 participants | Low Downgraded: risk of bias, imprecision |
Sexual adverse events Silodosin vs tamsulosin | RR 6.05 [3.55, 10.31] | 10 studies · 1849 participants | Moderate Downgraded: risk of bias |
Silodosin compared to naftopidil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia (short term)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Urologic symptom scores Silodosin vs naftopidil | no estimate extracted | 5 studies · 652 participants | Low Downgraded: risk of bias, inconsistency |
QoL Silodosin vs naftopidil | no estimate extracted | 5 studies · 652 participants | Low Downgraded: risk of bias, inconsistency |
Treatment withdrawal due to any reason Silodosin vs naftopidil | RR 1.25 [0.81, 1.93] | 4 studies · 659 participants | Low Downgraded: risk of bias, imprecision |
Cardiovascular adverse events Silodosin vs naftopidil | RR 1.02 [0.41, 2.56] | 5 studies · 808 participants | Low Downgraded: risk of bias, imprecision |
Sexual adverse events Silodosin vs naftopidil | RR 5.93 [2.16, 16.29] | 4 studies · 405 participants | Moderate Downgraded: risk of bias |
Silodosin compared to alfuzosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia (short term)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Urologic symptom scores Silodosin vs alfuzosin | no estimate extracted | 1 study · 60 participants | Low Downgraded: risk of bias, imprecision |
QoL Silodosin vs alfuzosin | no estimate extracted | 1 study · 60 participants | Moderate Downgraded: risk of bias |
Treatment withdrawal due to any reason Silodosin vs alfuzosin | no estimate extracted | 1 study · 60 participants | Low Downgraded: risk of bias, imprecision |
Cardiovascular adverse events Silodosin vs alfuzosin | RR 0.67 [0.36, 1.24] | 1 study · 60 participants | Low Downgraded: risk of bias, imprecision |
Sexual adverse events Silodosin vs alfuzosin | RR 37.21 [5.32, 260.07] | 1 study · 95 participants | Moderate Downgraded: risk of bias |